GSK ends cough programme
GSK Plc has stopped development of a small molecule drug for chronic cough following only limited efficacy for the product in a Phase 3 programme. However the drug will continue to be evaluated for irritable bowel syndrome. The drug, camlipixant, entered GSK’s portfolio with the acquisition of the Canadian company, BELLUS Health Inc in 2023. At the time, the acquisition was valued at $2 billion. Camlipixant is an antagonist of the P2X3 receptor, a type of receptor primarily found in sensory neurons.
